Detail Information of Xenobiotics
| General Information of Xenobiotics (ID: XEO00582) | ||||||
|---|---|---|---|---|---|---|
| Xenobiotics Name |
Diethyltoluamide
|
|||||
| Xenobiotics Type |
Pharmaceutical Agent(s)
|
|||||
| Classification |
Drug in Phase 3 Clinical Trial
|
|||||
| Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=4284"></iframe>
|
![]() |
||||
| 3D MOL | 2D MOL | |||||
| PubChem CID | ||||||
| DME(s) Modulated by This Xenobiotics | ||||||
| DME(s) Inhibited by This Xenobiotics | ||||||
| Acetylcholinesterase (ACHE) | DME Info | Homo sapiens | [1] | |||
| Butyrylcholine esterase (BCHE) | DME Info | Homo sapiens | [1] | |||
| Lauric acid omega-hydroxylase (CYP4A11) | DME Info | Homo sapiens | [2] | |||
| Dihydrotestosterone oxidoreductase (HSD3B1) | DME Info | Homo sapiens | [2] | |||
| DME(s) Induced by This Xenobiotics | ||||||
| Microsomal cytochrome MCB5 (CYB5A) | DME Info | Homo sapiens | [2] | |||
| Cytochrome P450 1A1 (CYP1A1) | DME Info | Homo sapiens | [2] | |||
| Cytochrome P450 1A2 (CYP1A2) | DME Info | Homo sapiens | [3], [2] | |||
| Cytochrome P450 2A13 (CYP2A13) | DME Info | Homo sapiens | [2] | |||
| Cytochrome P450 2A6 (CYP2A6) | DME Info | Homo sapiens | [3], [2] | |||
| Cytochrome P450 2B6 (CYP2B6) | DME Info | Homo sapiens | [3], [2] | |||
| Cytochrome P450 2C8 (CYP2C8) | DME Info | Homo sapiens | [2] | |||
| Cytochrome P450 2C9 (CYP2C9) | DME Info | Homo sapiens | [2] | |||
| Cytochrome P450 3A4 (CYP3A4) | DME Info | Homo sapiens | [3], [2] | |||
| Cytochrome P450 3A43 (CYP3A43) | DME Info | Homo sapiens | [2] | |||
| Cytochrome P450 3A5 (CYP3A5) | DME Info | Homo sapiens | [2] | |||
| Cytochrome P450 3A7 (CYP3A7) | DME Info | Homo sapiens | [2] | |||
| Glutathione S-transferase alpha-2 (GSTA2) | DME Info | Homo sapiens | [2] | |||
| NADPH-cytochrome P450 reductase (CPR) | DME Info | Homo sapiens | [2] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.


